Starpharma Holdings Limited (ASX: SPL) - Share Price
Current share price for SPL : $0.735 0.025 (3.52%)+
Starpharma Holdings Limited (SPL), an ASX-listed company, is a biotechnology company with over 20 years of experience in developing dendrimer technology for pharmaceutical applications. Their mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of their unique dendrimer technology.
SPL General Information +
| ASX Code | SPL |
| Website | http://www.starpharma.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 309 |
| SPL Share Price | $0.735 |
| Day High | $0.750 |
| Day Low | $0.705 |
| Last Close | $0.710 |
| SPL Share Price Movement | $0.03 ( 3.52% ) |
Prices as at 16:26, 3 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Starpharma Holdings Limited (SPL) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Interim | 1.5¢ | 100% | 25 Mar 1988 | 15 Apr 1988 | - | - | - |
See all dividends from Starpharma Holdings Limited (SPL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Starpharma Holdings Limited (SPL) price-sensitive announcements
SPL - Positive DEP HER2-Lu preclinical data support Phase 1 entry
Starpharma Holdings Limited announced positive preclinical results for its DEP® HER2-Lu ra
Starpharma Holdings Limited (SPL)
2 Jul 2026 | 9:22 AM
2 Jul 2026 | 9:22 AM
SPL - DEP radiopharmaceutical data supports patent application
Starpharma Holdings Limited announced the filing of a new patent application for its propr
Starpharma Holdings Limited (SPL)
2 Jul 2026 | 9:20 AM
2 Jul 2026 | 9:20 AM
SPL - Quarterly Activities/Appendix 4C Cash Flow Report
Starpharma Holdings Limited announced its quarterly activities and Appendix 4C cash flow r
Starpharma Holdings Limited (SPL)
29 Apr 2026 | 10:15 AM
29 Apr 2026 | 10:15 AM
SPL - FDA confirms path to DEP HER2 first-in-human study
Starpharma Holdings Limited, an innovative biotechnology company, announced the confirmati
Starpharma Holdings Limited (SPL)
21 Apr 2026 | 9:40 AM
21 Apr 2026 | 9:40 AM
Starpharma Holdings Limited (SPL) Recent ASX Announcements
SPL Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$9.99 | -$2.40 | 20.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$8.17 | -$2.00 | -48.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$15.64 | -$3.80 | -3.80% | 0.00 | 0.00 | 0.00% | 0.0% |
SPL Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $791M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,238M | -0.7857 | 0.0743 | 1.2000 | 75.8487 | 70.6000 | 32.0909 | 0.00% | 0.00% | 0.00% |
| Starpharma Holdings Limited (SPL) | $299M | 0.2071 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
SPL Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 15.60 | 0.00 |
| Market | 0.55 | 16.70 | 1.57 | 0.94 |
| Sector | 0.44 | 26.10 | 2.47 | 1.92 |
SPL Directors
| Name | Position | Start Date |
|---|---|---|
| Ms Cheryl Ann Maley | Chief Executive Officer, Managing Director | 8 Jan 2024 |
| Mr David McIntyre | Non-Executive Director | 1 Mar 2020 |
| Ms Lynda Cheng | Non-Executive Director | 1 Aug 2021 |
| Dr Jeff Davies | Non-Executive Director | 1 Apr 2022 |
| Dr Russell Basser | Non-Executive Director | 20 Feb 2023 |
| Mr Robert Bain Thomas | Non-Executive Director, Non-Executive Chairman | 4 Dec 2013 |
Starpharma Holdings Limited (SPL) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 16 Oct 2025 | THOMAS, Robert | Buy | Direct Shares | 450,000 | $0.279 | $125,471.000 |
| 5 Nov 2024 | THOMAS, Robert | Buy | Direct Shares | 300,000 | $0.093 | $28,000.000 |
| 23 Oct 2024 | THOMAS, Robert | Buy | Indirect Shares | 300,000 | $0.093 | $27,750.000 |
See all changes in directors' interest & trades for Starpharma Holdings Limited (SPL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
SPL Management
| Name | Position |
|---|---|
| Justin Cahill | Chief Financial Officer,Company Secretary |
SPL Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Starpharma Holdings Limited (SPL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 48,480,000 (11.80%) | Allianz SE and the entities |
| 29,838,184 (7.10%) | Robmar Investments Pty Umited |
| 26,680,974 (6.40%) | ICM Investment Management Ltd |
SPL Calendar of Events
| Date | Event |
|---|---|
| 17 February 2027 | Report (Interim) |
| 25 August 2026 | Report (Annual) |
| 25 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
